CHIEF EXECUTIVE OFFICER

Founded two technology companies, taking one public after it reached $120 million in annual revenue within 5 years of formation and the other to a run rate of $20 million within its first 3 years. Academic, entrepreneur, and author of five best-selling books: From Incremental to Exponential; Your Happiness Was Hacked; The Driver in the Driverless Car; Innovating Women; and The Immigrant Exodus.

Vivek has been a globally syndicated columnist for The Washington Post and has held appointments as Distinguished Fellow at Harvard Law School’s Labor and Worklife Program, Carnegie Mellon University, and Emory University; adjunct professor at Carnegie Mellon and Duke University; fellow at Stanford Law School and UC Berkeley; and head of faculty at Singularity University.

CHIEF MARKETING OFFICER

Served in senior leadership roles (C-Level, VP, Product Lead) at numerous technology companies, including Mozilla, Picarro, Silk, Joyent, Telefonica, and SightMachine. Broad experience across a wide range of technologies, including cloud computing, databases, AI + ML, industrial analytics, and scientific instruments. Led marketing and product marketing at Picarro, a leading manufacturer of Cavity Ring-Down Spectroscopy analyzers (backed by Greylock Ventures). Consults for the Linux Foundation on innovation and open source..

Alex has co-written four books with Vivek, including From Incremental to Exponential; Your Happiness Was Hacked; The Driver in the Driverless Car; and The Immigrant Exodus. Prior to his technology career, Alex was the Technology Editor of Businessweek.

SCIENTIFIC ADVISOR

Kandasamy Ravi (aka Ravi) is an experimental biologist with specialization in cancer genomics. He has a PhD in molecular biology and biotechnology from the National Research Center on Biotechnology and over 20 years of experience working in genomics at various capacities in pharma, start-up and academic centers.

Most recently he headed R&D and operations at C2i genomics where he built whole genome sequencing based ctDNA diagnostic products for a distributed model. Ravi worked in large pharma (BMS, GSK) for a decade and previously trained and worked at Cold Spring Harbor Labs (CSHL, NY) in cancer genomics.

AI/MACHINE LEARNING ADVISOR

Jagadish Venkataraman has a PhD in wireless communications and information theory from the University of Notre Dame. He spent the early parts of his career in the semiconductor and navigation industries. Hobby collaborations with a professor in UCSF in the biomedical engineering space triggered his passion for the Healthcare space.

Across companies like Alphabet, Tempus Labs and UnitedHealth Group, he has led research projects that have laid the foundation for perception targets in surgical robots, studied aging across different model organisms like yeast, mice etc., created a Generative Imaging based high throughput drug screening platform based on tumor derived Organoids and, lastly, are exploring opportunities for Gen AI in reducing the prevalent administrative burden in Healthcare in the US.

MEDICAL ADVISOR

Professor, Medicine, Harvard Medical School. Director of Henri and Belinda Termeer Center for Targeted Therapy, Cancer Center, Massachusetts General Hospital. Director of Clinical Research, Cancer Center, Massachusetts General Hospital.

Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer. In this context he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population

MEDICAL ADVISOR

Gastrointestinal Oncologist, Director of the Global Cancer Care Program, Medical Director Young Adult Colorectal Cancer Center, MGH Cancer Center.

Dr. Parikh is an expert in Gastrointestinal Cancers with a focus on Young Adults with Colorectal Cancer and also sees patients with Pancreatic Cancer. She sits on the NCCN guidelines committee for Colorectal Cancer.

MEDICAL ADVISOR

Professor of Medicine, Mayo Clinic College of Medicine and Science, Program Leader - Gene and Virus Therapy Program, Mayo Clinic Comprehensive Cancer Center, Director - Precision Cancer Therapeutics Program, Mayo Clinic Center for Individualized Medicine.

Dr. Borad's research focuses on development of precision medicine enabled diagnostics, therapeutics and platforms and development of gene and virus based therapies as anti-cancer agents. He also serves as the Chair for the International Cholangiocarcinoma Research Network (ICRN).

PATHOLOGY ADVISOR

An internationally recognized pathologist, researcher, educator, laboratory medical director. Dr. Amin has 22 years leadership experience in academic pathology departments with almost 14 years additionally as Pathology CLIA Laboratory Medical Director in tertiary-quaternary care hospitals.

Dr. Amin is currently the Divisional Medical Director and Vice President, West Division and Hospital Systems Operating Division at Labcorp, Clinical Professor of Pathology and Laboratory Medicine at the University of Tennessee Health Science Center, and Adjunct Clinical Professor of Urology at the USC Keck School of Medicine. At Labcorp, as the Medical Director for 2 of the company’s seven divisions, he leads the development and execution of the medical and science strategy for the Divisions to assure delivery of the highest quality of Lab solutions and diagnostics to Labcorp physicians and patients.

IP ADVISOR

JiNan has built her career from engineering to patent law and investment by transforming ideas into assets and connecting innovators to the resources they need to impact society for good. She believes that everyone has the power to create – and her work globally has focused on creating positive impact through intellectual property (IP) rights and data.

A Patent Attorney and former Patent Examiner with the US Patent & Trademark Office, JiNan is an IP attorney with experience across a wide range of technology fields, serving clients in the US and internationally, in her 25th year of practice. She is a registered patent attorney with the North Carolina Bar and the US Patent & Trademark Office; she is the founding partner of Neo IP in Durham, NC, USA (www.neoipassets.com).

SCIENTIFIC ADVISOR

Aswhin Gopinath has a Ph.D. in Electrical Engineering from Boston University applied physics at Boston University and MIT, focused on light transport in disordered media and biomolecular sensing. Post-PhD, Ashwin joined Caltech as a Postdoc and later became a research professor in bioengineering, working on DNA computation and the integration of semiconductors with biomolecules. After several years at Caltech, he transitioned to Google [X], where he continued his DNA computation research and developed generative algorithms for longitudinal data.

In 2019, Ashwin left Google to establish a lab at MIT (Joint appointment in MechE, BioE, and biophysics) focused on AI and biomolecule engineering. Concurrently, he co-founded Palamedrix, a proteomics company based on his Caltech work which was later acquired by somalogic.

Aswhwin’s startup Biostate.ai is developing a foundational model of biology.

STRATEGY AND TECHNOLOGY ADVISOR

Partner at Artiman Ventures; Board Member at Artiman Companies; Independent Director; former CEO of BioImagene (acquired by Roche); former CEO of Siemens Oncology; Adjunct Professor at Stanford School of Medicine.

Ajit is also serves on the Board of Directors of Max Healthcare based in New Delhi, India. His previous roles included President and CEO of the Oncology Care Systems Group, Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services. From 1989 to 1995, he was at Siemens Corporate Research working on Artificial Intelligence, Robotics, Computer Vision, and Image Analysis. During this time, he concurrently served on the faculty at Princeton University.

SCIENTIFIC ADVISOR

Patrick Pirrott holds a PhD in Neuroscience from the University of Strasbourg, France. He founded a consulting firm specializing in analytical services in material science for Fortune 500 companies and contributed to the development of a Luxembourgish government-operated biobank. Since 2011, Patrick has been with the Translational Genomics Research Institute in Phoenix, AZ, where he served as Technical Director before leading a major translational spectrometry facility.

He also spearheaded the expansion to City of Hope in Los Angeles. He focuses on cancer signaling and biomarkers, with notable publications in neurodegenerative disorders. Patrick is passionate about advancing alternatives to mass spectrometry, addressing its accessibility, complexity, cost, and throughput challenges.